The in vitro diagnostics market size has grown rapidly in recent years. It will grow from $136.55 billion in 2025 to $152.42 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to expansion of diagnostic testing volumes, growth in infectious disease screening, rising burden of chronic diseases, improvements in laboratory infrastructure, increasing healthcare access.
The in vitro diagnostics market size is expected to see rapid growth in the next few years. It will grow to $241.14 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to increasing adoption of decentralized diagnostics, rising investments in molecular testing technologies, expansion of personalized medicine diagnostics, growing demand for rapid and accurate testing, increasing integration of ai-driven diagnostics. Major trends in the forecast period include increasing adoption of point-of-care diagnostic devices, rising demand for molecular and immunoassay testing, growing use of automated laboratory systems, expansion of multiplex diagnostic platforms, enhanced focus on rapid testing.
The rising prevalence of cancer is expected to drive the growth of the in vitro diagnostics (IVD) market. Cancer encompasses over 100 different diseases that can develop in various parts of the body. The increasing incidence of cancer is largely attributed to lifestyle factors such as increased tobacco use, poor diet, physical inactivity, and environmental pollution, all of which elevate the risk of cancer across populations. In vitro diagnostics (IVDs) are a category of tests or medical devices that analyze samples taken from the human body, providing essential information for the screening, diagnosis, and treatment of cancer. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported that there were 1,958,310 new cancer cases and an estimated 609,820 cancer deaths in the United States in 2023. As a result, the growing prevalence of cancer is expected to propel the demand for in vitro diagnostics.
Major players in the in vitro diagnostics (IVD) market are incorporating advanced technologies, such as UIMG image technology and 2D decoder chips, to enhance diagnostic accuracy and efficiency, improve data analysis, optimize workflows, and ultimately deliver better patient outcomes. UIMG image technology is an advanced imaging technique used in diagnostics to capture and analyze high-resolution images, enhancing the visualization and interpretation of biological samples. For example, in November 2023, Newland, a Netherlands-based technology company in the EMEA region, launched a new IVD product line. This product line includes five barcode scanners that are compact, durable, and designed to optimize automated diagnostic processes, aiming to boost diagnostic speed and accuracy in response to the growing demand for efficient healthcare solutions.
In June 2025, bioMérieux, a France-based provider of in vitro diagnostics solutions, acquired Day Zero Diagnostics for approximately $25 million. This acquisition strengthens bioMérieux’s next-generation sequencing (NGS) capabilities and enhances its rapid diagnostics portfolio, allowing the company to better address antibiotic-resistant infections and improve the management of life-threatening infectious diseases. Day Zero Diagnostics, a US-based company, specializes in genome sequencing and machine learning technologies that enable the rapid identification of bacterial pathogens and their antibiotic resistance profiles directly from whole blood samples.
Major companies operating in the in vitro diagnostics market are Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Alere Inc., Arkray Inc., Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., bioMérieux SA, Grifols SA, Hologic Inc., Werfen SA, Laboratory Corporation, Luminex Corporation, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen NV, Quest Diagnostics Inc., QuidelOrtho Corporation, Sysmex Corporation, Illumina Inc., Menarini Silicon Biosystems SPA, SpeeDx Pty. Ltd., GENSPEED Biotech GmbH, Accelerate Diagnostics Inc., Merck KGaA, Caris Life Sciences Inc., Bio-Techne Corporation, Myriad Genetics Inc., Genomic Health Inc., Exact Sciences Crop., Natera Inc., Invitae Crop., Veracyte Inc.
North America was the largest region in the global in-vitro diagnostics market in 2025. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in vitro diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in vitro diagnostics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs are influencing the in vitro diagnostics market by increasing costs of imported analyzers, reagents, microfluidic components, and optical systems used across diagnostic platforms. North America and Europe are most affected due to reliance on globally sourced diagnostic equipment, while Asia-Pacific faces higher costs for reagent imports and exports. These tariffs are raising testing costs and delaying laboratory upgrades. However, they are also encouraging domestic manufacturing, regional reagent production, and strengthened local diagnostic supply chains.
The in vitro diagnostics market research report is one of a series of new reports that provides in vitro diagnostics market statistics, including in vitro diagnostics industry global market size, regional shares, competitors with a in vitro diagnostics market share, detailed in vitro diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro diagnostics industry. This in vitro diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
In vitro diagnostics (IVD) are tests performed on biological samples, such as blood, tissue, or urine, collected from the human body to identify diseases, conditions, or infections. Conducted outside the body in controlled environments like laboratories, these tests utilize specialized equipment and reagents. IVDs play a vital role in diagnosing various health conditions, guiding treatment decisions, and monitoring patient health over time.
The principal categories of in-vitro diagnostics equipment encompass point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices and equipment, and immunohematology diagnostic devices and equipment. Hematology instruments, for instance, are machines designed to analyze blood samples, perform blood counts, detect proteins or enzymes, and aid in the diagnosis of diseases or genetic defects. These devices and equipment are used in both public and private settings and involve instruments/equipment as well as disposables. The end-users for these tools include hospitals and clinics, diagnostic laboratories, and other relevant institutions.
The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The in vitro diagnostics market size is expected to see rapid growth in the next few years. It will grow to $241.14 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to increasing adoption of decentralized diagnostics, rising investments in molecular testing technologies, expansion of personalized medicine diagnostics, growing demand for rapid and accurate testing, increasing integration of ai-driven diagnostics. Major trends in the forecast period include increasing adoption of point-of-care diagnostic devices, rising demand for molecular and immunoassay testing, growing use of automated laboratory systems, expansion of multiplex diagnostic platforms, enhanced focus on rapid testing.
The rising prevalence of cancer is expected to drive the growth of the in vitro diagnostics (IVD) market. Cancer encompasses over 100 different diseases that can develop in various parts of the body. The increasing incidence of cancer is largely attributed to lifestyle factors such as increased tobacco use, poor diet, physical inactivity, and environmental pollution, all of which elevate the risk of cancer across populations. In vitro diagnostics (IVDs) are a category of tests or medical devices that analyze samples taken from the human body, providing essential information for the screening, diagnosis, and treatment of cancer. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported that there were 1,958,310 new cancer cases and an estimated 609,820 cancer deaths in the United States in 2023. As a result, the growing prevalence of cancer is expected to propel the demand for in vitro diagnostics.
Major players in the in vitro diagnostics (IVD) market are incorporating advanced technologies, such as UIMG image technology and 2D decoder chips, to enhance diagnostic accuracy and efficiency, improve data analysis, optimize workflows, and ultimately deliver better patient outcomes. UIMG image technology is an advanced imaging technique used in diagnostics to capture and analyze high-resolution images, enhancing the visualization and interpretation of biological samples. For example, in November 2023, Newland, a Netherlands-based technology company in the EMEA region, launched a new IVD product line. This product line includes five barcode scanners that are compact, durable, and designed to optimize automated diagnostic processes, aiming to boost diagnostic speed and accuracy in response to the growing demand for efficient healthcare solutions.
In June 2025, bioMérieux, a France-based provider of in vitro diagnostics solutions, acquired Day Zero Diagnostics for approximately $25 million. This acquisition strengthens bioMérieux’s next-generation sequencing (NGS) capabilities and enhances its rapid diagnostics portfolio, allowing the company to better address antibiotic-resistant infections and improve the management of life-threatening infectious diseases. Day Zero Diagnostics, a US-based company, specializes in genome sequencing and machine learning technologies that enable the rapid identification of bacterial pathogens and their antibiotic resistance profiles directly from whole blood samples.
Major companies operating in the in vitro diagnostics market are Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Alere Inc., Arkray Inc., Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., bioMérieux SA, Grifols SA, Hologic Inc., Werfen SA, Laboratory Corporation, Luminex Corporation, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen NV, Quest Diagnostics Inc., QuidelOrtho Corporation, Sysmex Corporation, Illumina Inc., Menarini Silicon Biosystems SPA, SpeeDx Pty. Ltd., GENSPEED Biotech GmbH, Accelerate Diagnostics Inc., Merck KGaA, Caris Life Sciences Inc., Bio-Techne Corporation, Myriad Genetics Inc., Genomic Health Inc., Exact Sciences Crop., Natera Inc., Invitae Crop., Veracyte Inc.
North America was the largest region in the global in-vitro diagnostics market in 2025. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in vitro diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in vitro diagnostics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs are influencing the in vitro diagnostics market by increasing costs of imported analyzers, reagents, microfluidic components, and optical systems used across diagnostic platforms. North America and Europe are most affected due to reliance on globally sourced diagnostic equipment, while Asia-Pacific faces higher costs for reagent imports and exports. These tariffs are raising testing costs and delaying laboratory upgrades. However, they are also encouraging domestic manufacturing, regional reagent production, and strengthened local diagnostic supply chains.
The in vitro diagnostics market research report is one of a series of new reports that provides in vitro diagnostics market statistics, including in vitro diagnostics industry global market size, regional shares, competitors with a in vitro diagnostics market share, detailed in vitro diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro diagnostics industry. This in vitro diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
In vitro diagnostics (IVD) are tests performed on biological samples, such as blood, tissue, or urine, collected from the human body to identify diseases, conditions, or infections. Conducted outside the body in controlled environments like laboratories, these tests utilize specialized equipment and reagents. IVDs play a vital role in diagnosing various health conditions, guiding treatment decisions, and monitoring patient health over time.
The principal categories of in-vitro diagnostics equipment encompass point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices and equipment, and immunohematology diagnostic devices and equipment. Hematology instruments, for instance, are machines designed to analyze blood samples, perform blood counts, detect proteins or enzymes, and aid in the diagnosis of diseases or genetic defects. These devices and equipment are used in both public and private settings and involve instruments/equipment as well as disposables. The end-users for these tools include hospitals and clinics, diagnostic laboratories, and other relevant institutions.
The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. in Vitro Diagnostics Market Characteristics
3. in Vitro Diagnostics Market Supply Chain Analysis
4. Global in Vitro Diagnostics Market Trends and Strategies
5. in Vitro Diagnostics Market Analysis of End Use Industries
7. Global in Vitro Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global in Vitro Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. in Vitro Diagnostics Market Segmentation
10. in Vitro Diagnostics Market Regional and Country Analysis
11. Asia-Pacific in Vitro Diagnostics Market
12. China in Vitro Diagnostics Market
13. India in Vitro Diagnostics Market
14. Japan in Vitro Diagnostics Market
15. Australia in Vitro Diagnostics Market
16. Indonesia in Vitro Diagnostics Market
17. South Korea in Vitro Diagnostics Market
18. Bangladesh in Vitro Diagnostics Market
19. Thailand in Vitro Diagnostics Market
20. Vietnam in Vitro Diagnostics Market
21. Malaysia in Vitro Diagnostics Market
22. Singapore in Vitro Diagnostics Market
23. Philippines in Vitro Diagnostics Market
24. Hong Kong in Vitro Diagnostics Market
25. New Zealand in Vitro Diagnostics Market
26. Taiwan in Vitro Diagnostics Market
27. South East Asia in Vitro Diagnostics Market
28. Western Europe in Vitro Diagnostics Market
29. UK in Vitro Diagnostics Market
30. Germany in Vitro Diagnostics Market
31. France in Vitro Diagnostics Market
32. Italy in Vitro Diagnostics Market
33. Spain in Vitro Diagnostics Market
34. Austria in Vitro Diagnostics Market
35. Belgium in Vitro Diagnostics Market
36. Denmark in Vitro Diagnostics Market
37. Finland in Vitro Diagnostics Market
38. Ireland in Vitro Diagnostics Market
39. Netherlands in Vitro Diagnostics Market
40. Norway in Vitro Diagnostics Market
41. Portugal in Vitro Diagnostics Market
42. Sweden in Vitro Diagnostics Market
42. Switzerland in Vitro Diagnostics Market
43. Eastern Europe in Vitro Diagnostics Market
44. Russia in Vitro Diagnostics Market
45. Czech Republic in Vitro Diagnostics Market
46. Poland in Vitro Diagnostics Market
47. Romania in Vitro Diagnostics Market
48. Ukraine in Vitro Diagnostics Market
49. North America in Vitro Diagnostics Market
50. USA in Vitro Diagnostics Market
51. Canada in Vitro Diagnostics Market
52. Mexico in Vitro Diagnostics Market
53. South America in Vitro Diagnostics Market
54. Brazil in Vitro Diagnostics Market
55. Chile in Vitro Diagnostics Market
56. Argentina in Vitro Diagnostics Market
57. Colombia in Vitro Diagnostics Market
58. Peru in Vitro Diagnostics Market
59. Middle East in Vitro Diagnostics Market
60. Saudi Arabia in Vitro Diagnostics Market
61. Israel in Vitro Diagnostics Market
62. Iran in Vitro Diagnostics Market
63. Turkey in Vitro Diagnostics Market
64. United Arab Emirates in Vitro Diagnostics Market
65. Africa in Vitro Diagnostics Market
66. Egypt in Vitro Diagnostics Market
67. Nigeria in Vitro Diagnostics Market
68. South Africa in Vitro Diagnostics Market
70. in Vitro Diagnostics Market Competitive Landscape and Company Profiles
71. in Vitro Diagnostics Market Other Major and Innovative Companies
74. in Vitro Diagnostics Market High Potential Countries, Segments and Strategies
75. Appendix
List of Tables
Executive Summary
In Vitro Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses in vitro diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for in vitro diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in vitro diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Diagnostic: Point-of-Care Diagnostics Devices And Equipment; Immunochemistry Diagnostic Devices And Equipment; Clinical Chemistry Diagnostics Devices And Equipment; Molecular Diagnostics Devices And Equipment; Microbiology Diagnostic Devices And Equipment; Hemostasis Diagnostic Devices And Equipment; Hematology Diagnostic Devices And Equipment; Immunohematology Diagnostic Devices And Equipment2) By Type of Expenditure: Public; Private
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
Subsegments:
1) By Point-Of-Care Diagnostics Devices And Equipment: Blood Glucose Monitoring; Pregnancy And Fertility Testing; Infectious Disease Testing; Cardiac Markers Testing; Coagulation Testing2) By Immunochemistry Diagnostic Devices And Equipment: Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA); Western Blot; Immunofluorescence Assay; Chemiluminescence Immunoassay (CLIA)
3) By Clinical Chemistry Diagnostic Devices And Equipment: Blood Glucose Testing; Cholesterol Testing; Liver Function Testing; Kidney Function Testing; Electrolyte Testing
4) By Molecular Diagnostics Devices And Equipment: PCR (Polymerase Chain Reaction) Instruments; Next-Generation Sequencing (NGS) Instruments; Microarray Instruments; FISH (Fluorescence In Situ Hybridization) Devices
5) By Microbiology Diagnostic Devices And Equipment: Microbial Culture Systems; Automated Identification Systems; Antimicrobial Susceptibility Testing Systems; Blood Culture Systems
6) By Hemostasis Diagnostic Devices and Equipment: Coagulation Analyzers; Thromboelastography Systems; Platelet Function Analyzers; Clotting Factor Analyzers
7) By Hematology Diagnostic Devices and Equipment: Hematology Analyzers; Hemoglobin Testing Systems; Complete Blood Count (CBC) Devices; Blood Cell Counters
8) By Immunohematology Diagnostic Devices and Equipment: Blood Typing Systems; Crossmatching Systems; Antibody Screening Systems; Blood Bank Analyzers
Companies Mentioned: Siemens Healthineers; F. Hoffmann-La Roche AG; Danaher Corporation; Abbott Laboratories Inc.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Alere Inc.; Arkray Inc.; Becton Dickinson and Company (BD); Bio-Rad Laboratories Inc.; bioMérieux SA; Grifols SA; Hologic Inc.; Werfen SA; Laboratory Corporation; Luminex Corporation; Ortho Clinical Diagnostics; PerkinElmer Inc.; Qiagen NV; Quest Diagnostics Inc.; QuidelOrtho Corporation; Sysmex Corporation; Illumina Inc.; Menarini Silicon Biosystems SPA; SpeeDx Pty. Ltd.; GENSPEED Biotech GmbH; Accelerate Diagnostics Inc.; Merck KGaA; Caris Life Sciences Inc.; Bio-Techne Corporation; Myriad Genetics Inc.; Genomic Health Inc.; Exact Sciences Crop.; Natera Inc.; Invitae Crop.; Veracyte Inc.
Countries: China; India; Japan; Australia; Indonesia; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; Taiwan; New Zealand; UK; Germany; France; Italy; Spain; Austria; Belgium; Denmark; Finland; Ireland; Netherlands; Norway; Portugal; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this In Vitro Diagnostics market report include:- Siemens Healthineers
- F. Hoffmann-La Roche AG
- Danaher Corporation
- Abbott Laboratories Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- Alere Inc.
- Arkray Inc.
- Becton Dickinson and Company (BD)
- Bio-Rad Laboratories Inc.
- bioMérieux SA
- Grifols SA
- Hologic Inc.
- Werfen SA
- Laboratory Corporation
- Luminex Corporation
- Ortho Clinical Diagnostics
- PerkinElmer Inc.
- Qiagen NV
- Quest Diagnostics Inc.
- QuidelOrtho Corporation
- Sysmex Corporation
- Illumina Inc.
- Menarini Silicon Biosystems SPA
- SpeeDx Pty. Ltd.
- GENSPEED Biotech GmbH
- Accelerate Diagnostics Inc.
- Merck KGaA
- Caris Life Sciences Inc.
- Bio-Techne Corporation
- Myriad Genetics Inc.
- Genomic Health Inc.
- Exact Sciences Crop.
- Natera Inc.
- Invitae Crop.
- Veracyte Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 152.42 Billion |
| Forecasted Market Value ( USD | $ 241.14 Billion |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 37 |
